A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Phase 3
1,035
about 2.2 years
18+
60 sites in AL, AZ, CA +22
About this study
Researchers are testing eloralintide compared to a placebo for weight loss in people with obesity or overweight who also have type 2 diabetes. The trial will last about 75 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Eloralintide
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Percent Change from Baseline in Body Weight
Secondary: Change from Baseline in Body Mass Index (BMI), Change from Baseline in Control of Eating Questionnaire (CoEQ) Score, Change from Baseline in EQ-5D-5L Score, Change from Baseline in Estimated Glomerular Filtration Rate (eGFR), Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Short Form-36 (SF-36 v2) Score, Change from Baseline in Systolic Blood Pressure, Change from Baseline in Waist Circumference
Endocrinology